Static carcinoembryonic antigen (CEA) levels are well‑established prognostic markers in patients with gastric cancer, but the significance of their dynamic trajectories over time has rarely been reported. We analysed the perioperative CEA levels (presurgery, early postsurgery, and late postsurgery) of 578 gastric cancer patients who underwent curative resection, with a median follow-up of 29 months. We used the entire cohort for k-means clustering. Survival differences between clusters were assessed using Kaplan–Meier analysis and Cox regression. Of the 578 patients, 15.57% exhibited elevated CEA levels before surgery (median 2.07 ng/mL), which then decreased to 3.29% (median 1.74 ng/mL) after surgery. However, after six months, a slight rebound was observed (18.51% elevated, median 2.98 ng/mL). K-means clustering identified three CEA trajectories: high, medium, and low (Calinski–Harabasz index: 358). Survival analysis demonstrated that higher CEA trajectories were associated with worse disease-free survival (DFS) and overall survival (OS). With the low cluster as a reference, multivariate Cox regression analysis revealed that a higher CEA trajectory was an independent prognostic factor, with an elevated risk in the high cluster (HR 2.64, 95% CI: 1.37-5.0), indicating that the high cluster had more than twice the mortality risk of the low cluster and that the medium cluster had a moderately increased mortality risk (HR 1.69, 95% CI: 1.0-2.85). Higher CEA trajectories are associated with a worse prognosis, highlighting the importance of enhanced monitoring for this group of patients. A machine learning-powered trajectory clustering algorithm employed. The trajectory cluster classification demonstrates a strong correlation with both disease-free survival and overall survival.
Aims: This study aims to develop a simple, clinically applicable classification system to predict pCR based on carcinoembryonic antigen (CEA) trajectory during NAC.Methods: This study included 366 AGC patients who received NAC followed by radical gastrectomy. CEA levels were measured before, during, and after NAC, with changes classified into three trajectory types: Type I (>=80% decline), Type II (>=40% but <80% decline), and Type III (<40% decline or increase). We analyzed associations between these CEA trajectories, pCR, lymph node remission, and survival.Results: pCR was achieved in 10.4% (38/366) of patients. pCR rates were significantly higher in Type I (41%) and Type II (15.8%) trajectories compared to Type III (6.7%). Lymph node remission also correlated with CEA trajectories, with Type I having the highest proportion of ypN0 (79.2%). Multivariate analysis identified CEA trajectory subtypes and tumor differentiation as independent predictors of pCR. This classification system proved robust across subgroups. Although no significant differences in overall survival were observed between subtypes, higher initial CEA levels were associated with worse survival.Conclusion: The trajectory of CEA change during NAC is a promising predictor of pCR in AGC. This simple and accessible classification system may facilitate personalized surgical strategies for patients with AGC.
1 June 2025 in Journal of Gastrointestinal Oncology
Background: Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Oxaliplatin (OXA) based therapy plus/minus targeted therapy and immune check point inhibitors is the standard first-line treatment for advanced GC; however, its clinical efficacy is often hindered by the development of drug resistance. Cyclin-dependent kinase 12 (CDK12), a transcriptional regulator linked to DNA repair, plays a crucial role in transcription, cancer progression as well as drug resistance, where its exact role is unclear. In this study, we will investigate the role of CDK12 in GC progression and its potential as a therapeutic target specifically to enhance the efficacy of OXA. Methods: CDK12 expression in GC tissues was analyzed by quantitative polymerase chain reaction (qPCR) and tissue microarrays (TMAs). A Kaplan-Meier survival analysis was conducted to assess the relationship between CDK12 levels and clinical outcomes. The effect of the CDK12 inhibitor combined with OXA was evaluated through in vivo and in vitro models. RNA-sequencing and western blots were used to investigate the molecular mechanisms of CDK12 inhibitor sensitizing OXA. Results: CDK12 exhibited significant amplification frequency in GC. The Mendelian-randomization analysis revealed a positive causal association between elevated CDK12 expression and an increased risk of GC. Additionally, CDK12 was significantly overexpressed in GC tissues compared with adjacent normal tissues, and its high expression was significantly associated with a worse prognosis. The functional assays revealed that combining the CDK12 inhibitor THZ531 with OXA synergistically suppressed GC cell proliferation, induced apoptosis, and reduced colony formation in vitro, while substantially inhibiting tumor growth in xenograft models. Mechanistically, CDK12 inhibition disrupted MAPK signaling, leading to enhanced OXA-induced DNA damage and potentiated anti-tumor effects. Conclusions: Our findings suggest that CDK12 inhibition may represent a promising strategy for overcoming OXA resistance and improving GC treatment outcomes.
Carbohydrate Antigen 125 (CA125), a tumor-associated glycoprotein, is an established prognostic marker in gastric cancer. However, the trajectory of CA125